Cargando…
Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471935/ https://www.ncbi.nlm.nih.gov/pubmed/34579183 http://dx.doi.org/10.3390/vaccines9090946 |
_version_ | 1784574595504799744 |
---|---|
author | Lebeau, Grégorie Lagrave, Alisé Ogire, Eva Grondin, Lauriane Seriacaroupin, Soundary Moutoussamy, Cédric Mavingui, Patrick Hoarau, Jean-Jacques Roche, Marjolaine Krejbich-Trotot, Pascale Desprès, Philippe Viranaicken, Wildriss |
author_facet | Lebeau, Grégorie Lagrave, Alisé Ogire, Eva Grondin, Lauriane Seriacaroupin, Soundary Moutoussamy, Cédric Mavingui, Patrick Hoarau, Jean-Jacques Roche, Marjolaine Krejbich-Trotot, Pascale Desprès, Philippe Viranaicken, Wildriss |
author_sort | Lebeau, Grégorie |
collection | PubMed |
description | The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1–DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness. |
format | Online Article Text |
id | pubmed-8471935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84719352021-09-28 Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine Lebeau, Grégorie Lagrave, Alisé Ogire, Eva Grondin, Lauriane Seriacaroupin, Soundary Moutoussamy, Cédric Mavingui, Patrick Hoarau, Jean-Jacques Roche, Marjolaine Krejbich-Trotot, Pascale Desprès, Philippe Viranaicken, Wildriss Vaccines (Basel) Review The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1–DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness. MDPI 2021-08-25 /pmc/articles/PMC8471935/ /pubmed/34579183 http://dx.doi.org/10.3390/vaccines9090946 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lebeau, Grégorie Lagrave, Alisé Ogire, Eva Grondin, Lauriane Seriacaroupin, Soundary Moutoussamy, Cédric Mavingui, Patrick Hoarau, Jean-Jacques Roche, Marjolaine Krejbich-Trotot, Pascale Desprès, Philippe Viranaicken, Wildriss Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine |
title | Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine |
title_full | Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine |
title_fullStr | Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine |
title_full_unstemmed | Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine |
title_short | Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine |
title_sort | viral toxin ns1 implication in dengue pathogenesis making it a pivotal target in development of efficient vaccine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471935/ https://www.ncbi.nlm.nih.gov/pubmed/34579183 http://dx.doi.org/10.3390/vaccines9090946 |
work_keys_str_mv | AT lebeaugregorie viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT lagravealise viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT ogireeva viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT grondinlauriane viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT seriacaroupinsoundary viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT moutoussamycedric viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT mavinguipatrick viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT hoaraujeanjacques viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT rochemarjolaine viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT krejbichtrototpascale viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT despresphilippe viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine AT viranaickenwildriss viraltoxinns1implicationindenguepathogenesismakingitapivotaltargetindevelopmentofefficientvaccine |